Qiagen (QGEN) Cash & Equivalents (2009 - 2026)

Qiagen (QGEN) has 18 years of Cash & Equivalents data on file, last reported at $646.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 1.18% year-over-year to $646.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646.3 million (up 1.18% YoY) and the FY2025 annual result came in at $839.0 million, up 26.44% from the prior year.
• Cash & Equivalents slipped to $646.3 million in Q1 2026 per QGEN's latest filing, from $839.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.4 billion in Q3 2025, with the low at $359.2 million in Q1 2023.
• Average Cash & Equivalents over 5 years is $741.4 million, with a median of $665.8 million recorded in 2023.
• Year-over-year, Cash & Equivalents jumped 105.91% in 2022 and sank 54.39% in 2023.
• Qiagen's Cash & Equivalents stood at $1.3 billion in 2022, then plunged by 47.46% to $668.1 million in 2023, then dropped by 0.68% to $663.6 million in 2024, then climbed by 26.44% to $839.0 million in 2025, then slipped by 22.97% to $646.3 million in 2026.
• Business Quant data shows QGEN's Cash & Equivalents at $646.3 million in Q1 2026, $839.0 million in Q4 2025, and $1.4 billion in Q3 2025.